Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Payables (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Payables for 10 consecutive years, with $11.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 54.44% year-over-year to $11.6 million, compared with a TTM value of $11.6 million through Dec 2025, down 54.44%, and an annual FY2025 reading of $11.6 million, down 54.44% over the prior year.
  • Payables was $11.6 million for Q4 2025 at Zevra Therapeutics, up from $11.1 million in the prior quarter.
  • Across five years, Payables topped out at $25.5 million in Q4 2024 and bottomed at $516000.0 in Q4 2021.
  • Average Payables over 5 years is $11.1 million, with a median of $11.1 million recorded in 2025.
  • The sharpest move saw Payables crashed 97.03% in 2021, then skyrocketed 1095.54% in 2022.
  • Year by year, Payables stood at $516000.0 in 2021, then surged by 1095.54% to $6.2 million in 2022, then soared by 126.73% to $14.0 million in 2023, then soared by 82.0% to $25.5 million in 2024, then crashed by 54.44% to $11.6 million in 2025.
  • Business Quant data shows Payables for ZVRA at $11.6 million in Q4 2025, $11.1 million in Q3 2025, and $15.8 million in Q2 2025.